ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.

Daniel A Pollyea et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.